ClinicalTrials.gg
Sign In
Not yet recruitingNCT07874945Updated Oct 15, 2026

Peripheral Vascular Effects of Insulin in Obesity

An Early Phase 1 interventional study of human insulin in Obesity (BMI>30) and Insulin Resistance, sponsored by University of Missouri-Columbia. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Missouri-Columbia · Early Phase 1, Interventional, and Basic science

Updated Oct 15, 2026Newly registeredGo to Updates ↓
Phase
Early Phase 1
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Successful completion of this project will advance our understanding of the role sympathetic nervous system overactivity plays in driving skeletal muscle malperfusion during hyperinsulinemia and consequently impaired glucose uptake in obesity.

02

Conditions studied

  • Obesity (BMI>30)
  • Insulin Resistance
03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's planned enrollment of 64 is below the median of 77 across 5,084 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Missouri-Columbia is the lead sponsor of 364 studies on the registry; 70 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 29 (69%) have results posted.

Browse University of Missouri-Columbia studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 18 to 65 years of age

Individuals with obesity and comorbid IR

  • BMI 30-45 kg/m2
  • Waist circumference ≥102 cm (men) or ≥88 cm (women)
  • HOMA-IR ≥2.5

Healthy normal weight adults

  • BMI 18-25 kg/m2
  • Waist circumference \<94 cm (men) and \<80 cm (women)
  • HOMA-IR \<2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding
  • Unable to provide consent
  • Diabetes or polycystic ovarian syndrome
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
  • Nerve/neurologic disease
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Current smoking, tobacco, nicotine use
  • Use of pharmacological therapy for weight loss
  • Body weight change >10% within the last 6 months
  • Sensitivity to lidocaine
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
  • History of hypersensitivity to nitrates
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Healthy normal weight adults

    Healthy normal weight adults

    Drug: human insulin

  • Experimental
    Individuals with obesity and comorbid IR

    Individuals with obesity and comorbid insulin resistance

    Drug: human insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Forearm blood flow

    Time frame: 5-minute resting average

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2031, 54 months later.

Of 71 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 78. This study's planned 54 months is above that.

Counting every sponsor, half of 328 studies reached it within 11 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2026
First posted
Oct 15, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874945
Lead sponsor
University of Missouri-Columbia
Responsible party
Jacqueline K Limberg, PhD (Associate Professor, University of Missouri-Columbia) — Principal investigator
First posted
Oct 15, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Jacqueline Limberg
Contact
limberglab@missouri.edu
573-882-2544

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin

Other studies in this condition

Obesity →

Other studies from this sponsor

University of Missouri-Columbia →

Start the discussion